Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Breakthrough Therapy designation for pain associated with DPN granted by FDA
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Around 7% of the Indian population suffers from IBS
Subscribe To Our Newsletter & Stay Updated